Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Tables)

Stockholders’ Equity (Tables)
9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Outstanding Warrants


Shares Underlying              
Outstanding     Exercise     Expiration  
Warrants     Price     Date  
20,174     $ 7.1875       September 24, 2025  




On June 22, 2022, prior to the close of the Nasdaq market, 1,498,128 shares of common stock were granted to employees, consultants, and directors issuable upon exercise of outstanding stock options under the Company’s 2019 Equity Incentive Plan at an exercise price of $7.63 per share, which was the most recent prior closing share price on June 21, 2022. The options had a fair value on the grant date of $9,512,356, based on a risk-free rate of 3.2% and an annualized volatility of 106%, of which $3,032,062 was expensed through September 30, 2023 and $6,480,294 will be expensed in the future if and as vesting occurs. Vesting will be based on time of service over a four year period and certain additional performance milestones for senior management, primarily related to the Phase III clinical trial.